Tasimelteon

Tasimelteon
Clinical data
Trade namesHetlioz, Hetlioz LQ
AHFS/Drugs.comMonograph
MedlinePlusa615004
License data
Dependence
liability		Low[1]
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailabilitynot determined in humans[2]
Protein binding89–90%
Metabolismextensive liver, primarily CYP1A2 and CYP3A4-mediated
Elimination half-life0.9–1.7 h / 0.8–5.9 h (terminal)
Excretion80% in urine, 4% in feces
Identifiers
  • (1R, 2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.114.889 Edit this at Wikidata
Chemical and physical data
FormulaC15H19NO2
Molar mass245.322 g·mol−1
3D model (JSmol)
  • CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2
  • InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1 ☒N
  • Key:PTOIAAWZLUQTIO-GXFFZTMASA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration (FDA)[3] in January 2014, for the treatment of non-24-hour sleep–wake disorder (also called non-24, N24 and N24HSWD).[4] In June 2014, the European Medicines Agency (EMA) accepted an EU filing application for tasimelteon[5] and in July 2015, the drug was approved in the European Union for the treatment of non-24-hour sleep-wake rhythm disorder in totally blind adults,[6] but not in the case of non-24 in sighted people.

The most common side effects include headache, somnolence, nausea (feeling sick) and dizziness.[7]

  1. ^ Kim HK, Yang KI (December 2022). "Melatonin and melatonergic drugs in sleep disorders". Translational and Clinical Pharmacology. 30 (4): 163–171. doi:10.12793/tcp.2022.30.e21. PMC 9810491. PMID 36632077.
  2. ^ "Tasimelteon Advisory Committee Meeting Briefing Materials" (PDF). Vanda Pharmaceuticals Inc. November 2013.
  3. ^ "FDA transcript approval minutes" (PDF). FDA. November 14, 2013.
  4. ^ Food and Drug Administration (January 31, 2014). "FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder" (Press release). FDA. Archived from the original on February 2, 2014. Retrieved December 16, 2019.
  5. ^ "tasimelteon (Hetlioz) UKMi New Drugs Online Database". Archived from the original on June 29, 2016. Retrieved August 6, 2014.
  6. ^ "Hetlioz Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind". MarketWatch. 7 July 2015. Archived from the original on 9 July 2015. Retrieved 8 July 2015 – via PR Newswire.
  7. ^ Cite error: The named reference Hetlioz EPAR was invoked but never defined (see the help page).